Europe Non-Alcoholic Steatopatitis Market Competitive
Landscape, and Trends by Forecast 2028
The Europe non-alcoholic steatopatitis market is expected to reach US$ 6,765.21 million by 2028 from US$ 496.83 million in 2021. The market is estimated to grow at a CAGR of 45.2% from 2021 to 2028.
Europe non-alcoholic steatopatitis market (NASH) is often underdiagnosed, highlighting the critical need for increased awareness among the general public and primary care physicians (PCPs). A well-defined referral pathway and early detection are crucial. By establishing clear patient pathways and implementing public awareness campaigns, more individuals can be appropriately identified and referred to specialists for comprehensive evaluation, thus expanding the patient pool for specialized care.
Efforts to raise NASH awareness have gained momentum. The NASH Education Program launched a public education campaign on "International NASH Day," June 12, 2018, aiming to increase understanding of non-alcoholic fatty liver disease (NAFLD) and its more advanced form, NASH, which affects over approximately 115 million individuals. Similarly, NASH 24X7, a digital platform dedicated to raising awareness about the NASH epidemic, undertook several initiatives on International NASH Day in 2019. These included support for healthcare professionals (HCPs), patient awareness programs, and press/TV releases. Notably, NASH Crusaders, in collaboration with HCPs across India, conducted numerous awareness and education workshops of varying scales, focusing on liver health and the importance of a healthy lifestyle in preventing NAFLD/NASH. Public outreach on International NASH Day also involved press releases and television programs disseminated through digital and print media.
The Europe non-alcoholic steatopatitis market is anticipated to experience substantial growth (CAGR) during the forecast period.
Europe non-alcoholic steatopatitis market Segmentation
The Europe non-alcoholic steatopatitis market is segmented based on product, application, sales channel, and country.
Key players in the Europe non-alcoholic steatopatitis market include Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, ONE WAY LIVER SI, BioPredictive S.A.S, Siemens Healthineers AG, and Laboratory Corporation of America Holdings. These companies are strategically focusing on organic growth strategies, such as product launches and expansions, to maintain their competitive edge in this dynamic market.
For example, in November 2021, GENFIT announced that its NIS4 technology demonstrated unique performance in identifying patients with "at-risk" NASH in a Stage 1 study conducted by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium.
Other Reports:
Europe Cosmeceuticals Market: https://business-news-insights.blogspot.com/2025/05/europe-cosmeceuticals-market-key.html
Europe Skin Care Products Market: https://sites.google.com/view/skin-care-products-market-e/home
Europe Graphene Market: https://penzu.com/p/5d7938edbf3bb185
Europe Methanol Market: https://github.com/SuryakantGadekar/Business-Market-Insights/issues/44
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
Author’s Bio:
Suryakant Gadekar
Senior Market Research Expert at Business Market Insights
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.